These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10541776)

  • 1. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions.
    Sekine Y; Rikihisa T; Ogata H; Echizen H; Arakawa Y
    Eur J Clin Pharmacol; 1999 Oct; 55(8):583-7. PubMed ID: 10541776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
    Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
    Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
    Zhang W; Bymaster FP
    Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus.
    Matsui-Sakata A; Ohtani H; Sawada Y
    Drug Metab Pharmacokinet; 2005 Oct; 20(5):368-78. PubMed ID: 16272755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
    Silvestre JS; Prous J
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.
    Nguyen TT; Pariente A; Montastruc JL; Lapeyre-Mestre M; Rousseau V; Rascol O; Bégaud B; Montastruc F
    Br J Clin Pharmacol; 2017 Mar; 83(3):612-622. PubMed ID: 27687785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
    Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
    Kroeze WK; Hufeisen SJ; Popadak BA; Renock SM; Steinberg S; Ernsberger P; Jayathilake K; Meltzer HY; Roth BL
    Neuropsychopharmacology; 2003 Mar; 28(3):519-26. PubMed ID: 12629531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.
    Richelson E; Souder T
    Life Sci; 2000 Nov; 68(1):29-39. PubMed ID: 11132243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
    Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
    Hameg A; Bayle F; Nuss P; Dupuis P; Garay RP; Dib M
    Biochem Pharmacol; 2003 Feb; 65(3):435-40. PubMed ID: 12527336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
    Raviña E; Casariego I; Masaguer CF; Fontenla JA; Montenegro GY; Rivas ME; Loza MI; Enguix MJ; Villazon M; Cadavid MI; Demontis GC
    J Med Chem; 2000 Nov; 43(24):4678-93. PubMed ID: 11101359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine and serotonin receptor binding and antipsychotic efficacy.
    Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
    Neuropsychopharmacology; 2007 Aug; 32(8):1715-26. PubMed ID: 17251913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-binding profiles of neuroleptics.
    Hyttel J; Larsen JJ; Christensen AV; Arnt J
    Psychopharmacology Suppl; 1985; 2():9-18. PubMed ID: 2860665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
    Leysen JE; Janssen PM; Schotte A; Luyten WH; Megens AA
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S40-54. PubMed ID: 7530377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of serotonin and dopamine receptor binding in antipsychotic efficacy.
    Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
    Prog Brain Res; 2008; 172():155-75. PubMed ID: 18772032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase.
    Montastruc F; Palmaro A; Bagheri H; Schmitt L; Montastruc JL; Lapeyre-Mestre M
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1556-65. PubMed ID: 26256010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.